BRYAN-GARNIER-&-CO
European investment bank Bryan, Garnier & Co today presented a study that clearly refutes the widespread structural undervaluation of European software vendors. When the usual EV/sales multiples (enterprise value / expected sales for the next year) are related to the average expected growth over three years (CAGR), European software vendors are even trading at a valuation premium of around nine percent (eight percent in the case of SaaS providers) compared to their US competitors.
For this analysis, software analyst Gregory Ramirez compared the valuations of all 95 European-listed and 97 US-listed software vendors between 2006 and 2020, for which there is historical analyst consensus data from Refinitiv. These companies include 29 European and 67 US SaaS vendors.
A superficial look at the simple sales multiples shows that the US providers' multiple of 9.9 over the last 15 years is significantly higher than the 5.6 of their European competitors. However, if the stock market value is not only assessed on the basis of the simple sales multiple, but average growth1 is taken into account and both are placed in relation to each other, a completely different picture emerges. This puts the significance of the sales expectation for the next year into perspective.
For example: if in April 2021 Salesforce shares were trading at a revenue multiple of 10 (10x expected revenue in 2022) and the expected average revenue growth (CAGR) for 2020-2023 is 20%, the ratio is 10 / 0.2 / 100 and the newly calculated ratio is 0.50. The analyst did this calculation for the 15 years up to April 2021 and came up with a surprising result, which is that the valuations of software companies on the European stock exchanges are not only on par with the companies listed in the US, they are slightly higher. For the Europeans, this results in an average valuation that is nine percent higher than that of their US competitors. The same principle applied to the 29 or 67 (US) listed SaaS providers over a four-year period yields almost the same result: here, the average premium is eight percent.
Ramirez explains: "This picture is much closer to the reality of the stock market valuation. This weighting with the average growth rate normalizes the multiples and thus relativises the significance of the short-term growth expectation for a single year.”
The study also shows that the differences in the individual valuations of software providers listed in Europe are wider than those of their US competitors. This dispersion cannot be explained by a significant number of loss-making companies among European software vendors, nor by the liquidity of their shares. Contrary to another common prejudice, the most highly valued European software stocks are by no means always the most liquid, nor are they necessarily listed on the most liquid markets.
Valuation is not decided by the stock market
Bryan, Garnier & Co explain that the heterogeneity of the valuation of European software providers is a result of very different business models, track records and corporate governance. Above all, the degree of maturity of the European companies is very different, while US companies almost always have a long maturation process with numerous financing rounds behind them before going public.
"This makes it clear that the stock exchange location is not decisive for the valuation of a software company. It's all about the quality of the business model and management, the degree of maturity and the track record to date ," explains Greg Revenu, Managing Partner of Bryan, Garnier & Co. This is an important insight, he says, "because for Europeans an IPO in the USA is usually associated with many difficulties .” Pierre Kiecolt-Wahl, Partner and Head of ECM at Bryan, Garnier & Co adds: "If the stock market success of European software companies is ultimately independent of the chosen stock exchange, there is not the slightest argument against an IPO on a European stock exchange. "
WEBINAR:
Debunking the software valuation gap: European software companies going public in the US
Bryan, Garnier & Co will be hosting a webinar on Thursday 27 May
, 10h CET – 10h45
to discuss the report findings in more detail. Join us >>
About Bryan, Garnier & Co (www.bryangarnier.com )
Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik and New York.
1 CAGR - in this case a three-year moving average of the expected growth rates of the current year and the next two years
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005057/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 01:00:00 CET | Press release
Stakeholder base expands with participation from an individual-investor-oriented fund, alongside corporate and individual investors, bringing Total Funding to USD 38M Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helic
Andersen Consulting udvider sin tilstedeværelse gennem samarbejde med Hilal Technology4.12.2025 23:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Hilal Technology for at styrke sine kompetencer inden for digital infrastruktur, cybersikkerhed og AI. Med tilstedeværelse i Bahrain, Saudi-Arabien, De Forenede Arabiske Emirater, Oman og Indien leverer Hilal Technology et komplet spektrum af digital infrastruktur og managed services inden for cloudcomputing, cybersikkerhed, enterprise ai og systemintegration. Deres ydelser omfatter cloudtjenester, sikkerheds- og netværksdrift, implementering af ERP og applikationer samt udvikling af generative ai-kapaciteter. Med et team på mere end 250 fagfolk servicerer firmaet en bred vifte af brancher, herunder den finansielle sektor, olie og gas, logistik og den offentlige sektor. "Transformation er mere end systemer; det handler om parathed, tillid og løbende samarbejde," udtaler Roshan George, direktør for Hilal Technology. "Vi er begejstrede for at samarbejde med Andersen Consulting og levere skalerbare løsninger, der matcher tempoet i den dig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
